



Azathioprine treatment in two children with Henoch–Schönlein purpura nephritis

Meltem A. Melikoğlu^{1,3}, Mehmet Melikoğlu², Emine E. Ergül³

¹Department of Rheumatology, Faculty of Medicine, Ataturk University, Erzurum, Turkey

²Department of Dermatology, Faculty of Medicine, Ataturk University, Erzurum, Turkey

³Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Ataturk University, Erzurum, Turkey

To the Editor:

We read the valuable article of Jung [1] presenting Henoch–Schönlein purpura nephritis (HSPN) and colitis in an adult patient with alcoholic liver cirrhosis. We aimed to contribute to this article by sharing our two years follow up results of two patients with HSPN.

Case 1: Sixteen year-old boy was hospitalised to our clinic with purpura, arthritis and abdominal pain. We diagnosed the case as Henoch–Schönlein purpura (HSP) based on the typical presentation and supportive therapy with hydration, rest and analgesics were initiated. After one week, his urinalysis revealed significant proteinuria (3.45 g/day). However, his family rejected renal biopsy.

Case 2: Fourteen year-old boy was referred to our clinic by Department of Dermatology due to HSP related purpura, arthralgia and abdominal pain. He was hospitalised and supportive therapy was recommended. In a two-week period, significant proteinuria (3.2 g/day) was presented and similarly, renal biopsy was rejected.

For both patients, azathioprine (AZA; 2 mg/day) + corticosteroid (CS; 1 mg/kg/day at the beginning and tapered down) and angiotensin converting enzyme inhibitors (ACE-I) were started. Abdominal pain and purpura were improved in both patients, but proteinuria persisted. Pro-

teinuria began to decrease after two months and urinalysis was normal at the end of six months. CS was stopped but AZA + ACE-I were continued for one year. After two years follow-up, no relaps was seen in both patients.

HSP is one of the most common vasculitides in children. Although HSP is considered to be self-limiting, approximately 7% of the cases will develop renal involvement [2]. Older children and adults are at increased risk for nephritis [3]. The diagnosis of HSPN is based upon the clinical presentation. The urinalysis reveals hematuria or proteinuria. A kidney biopsy can be done to establish the diagnosis, but this invasive procedure is generally reserved for uncertain diagnosis, proteinuria >1 g/day and/or impaired renal function.

Appropriate treatment decision may be difficult due to the large proportion of patients with a favorable prognosis. Patients with limited evidence of renal involvement may be followed closely without specific treatment. Current guideline has recommended that children with HSPN with persistent proteinuria should be treated with ACE-I or angiotensin receptor blockers, and those with persistent proteinuria after this regimen should be treated with a 6-month course of CSs [2]. However, due to the possibility of a potentially aggressive glomerular inflammation, CSs and various immunosuppressive agents (cyclophosphamide, azathioprin, calcineurin inhibitors and others), with or without adjuvant therapies may be needed at the beginning and have been used in HSPN [1,2]. In spite of the positive results, these treatments have been found to be effective in small-sample patient studies. Due to the favorable prognosis in most of the patients with HSP, it may be hard to relate these positive results directly to the treatment regimens. In regards to

Received November 14, 2016; **Revised** December 1, 2016;

Accepted December 7, 2016

Correspondence: Mehmet Melikoğlu

Department of Dermatology, Faculty of Medicine, Ataturk University, Erzurum 25240, Turkey. E-mail: mmelikoglu@gmail.com

Copyright © 2017 by The Korean Society of Nephrology

© This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

significant renal involvement, we wanted to contribute to the previous data by sharing our two-years follow-up results in two children with HSPN. Well-designed prospective randomized controlled studies are still needed for these cases.

Conflicts of interest

All authors have no conflicts of interest to declare.

References

- [1] Jung JH: Henoch-Schönlein purpura nephritis and colitis in an adult patient with alcoholic liver cirrhosis. *Kidney Res Clin Pract* 35:190-191, 2016
- [2] Chen JY, Mao JH: Henoch-Schönlein purpura nephritis in children: incidence, pathogenesis and management. *World J Pediatr* 11:29-34, 2015
- [3] Kang Y, Park JS, Ha YJ, Kang MI, Park HJ, Lee SW, Lee SK, Park YB: Differences in clinical manifestations and outcomes between adult and child patients with Henoch-Schönlein purpura. *J Korean Med Sci* 29:198-203, 2014